(NP (NP (NN Activation)) (PP (IN of) (NP (NN NF-kappa) (NN B))) (PP (IN by) (NP (NN interleukin) (CD 2))) (PP (IN in) (NP (JJ human) (NN blood) (NNS monocytes))) (. .))
(S (NP-SBJ (PRP We)) (VP (VBP report) (ADVP (RB here)) (SBAR (IN that) (S (NP-SBJ-28 (NP (NN interleukin) (CD 2)) (PRN (-LRB- -LRB-) (NP (NN IL-2)) (-RRB- -RRB-))) (VP (VBZ acts) (PP (IN on) (NP (JJ human) (NN blood) (NNS monocytes))) (PP (IN by) (S (NP-SBJ (-NONE- *-28)) (VP (VBG enhancing) (NP (NP (NN binding) (NN activity)) (PP (IN of) (NP (DT the) (NN transcription) (NN factor) (NN NF-kappa) (NN B))) (PP (TO to) (NP (NP (PRP$ its) (NN consensus) (NN sequence)) (PP (IN in) (NP (NP (NP (DT the) (JJ 5') (JJ regulatory) (NN enhancer) (NN region)) (PP (IN of) (NP (DT the) (NN IL-2) (NN receptor) (NN alpha) (NN chain)))) (PRN (-LRB- -LRB-) (NP (NN p55)) (-RRB- -RRB-)))))))))))))) (. .))
(S (ADVP (RB Similarly)) (, ,) (NP-SBJ (NN IL-2)) (VP (VBZ activates) (NP (NN NF-kappa) (NN B)) (PP-COOD (PP (IN in) (NP (DT the) (JJ human) (JJ monocytic) (NN cell) (NN line) (NN U) (CD 937))) (, ,) (CC but) (PP (RB not) (IN in) (NP (VBG resting) (JJ human) (NNS T-cells))))) (. .))
(S (NP-SBJ (DT This) (NN effect)) (VP-COOD (VP (VBZ is) (ADJP-PRD (JJ detectable)) (PP-TMP (IN within) (NP (CD 15) (NN min)))) (CC and) (VP (VBZ peaks) (PP-TMP (NP (CD 1) (NN h)) (IN after) (NP (NP (NN exposure)) (PP (TO to) (NP (NN IL-2))))))) (. .))
(S (NP-SBJ-29 (VBN Enhanced) (NN NF-kappa) (NN B) (NN binding) (NN activity)) (VP (VBZ is) (VP (VBN followed) (NP (-NONE- *-29)) (PP (IN by) (NP-LGS (NP (JJ functional) (NN activation)) (WHPP-105 (IN in) (SBAR-COOD (SBAR (WHNP (IN that)) (S (NP-SBJ-30 (NP (NN inducibility)) (PP (IN of) (NP (DT the) (NN IL-2) (NN receptor) (NN alpha) (NN chain)))) (VP (VBZ is) (VP (VBN mediated) (NP (-NONE- *-30)) (PP (IN by) (NP-LGS (VBN enhanced) (NN NF-kappa) (NN B) (NN binding))) (PP (-NONE- *T*-105)))))) (CC and) (SBAR (WHNP (IN that)) (S (NP-SBJ-31 (NP (DT a) (JJ heterologous) (NN promoter)) (VP (VBG containing) (NP (NP (NP (DT the) (NN NF-kappa) (NN B) (NN consensus) (NN sequence)) (PRN (-LRB- -LRB-) (NP-COOD (NP (CD -291)) (TO to) (NP (CD -245))) (-RRB- -RRB-))) (PP (IN of) (NP (DT the) (NN IL-2) (NN receptor) (NN alpha) (NN chain) (NN gene)))))) (VP (VBZ is) (VP (VBN activated) (NP (-NONE- *-31)) (PP (-NONE- *T*-105)))))))))))) (. .))
(S-COOD (S (PP (IN In) (NP (NN addition))) (, ,) (NP-SBJ-32 (NN IL-2)) (VP (VBZ is) (ADJP-PRD (JJ capable) (PP (IN of) (S (NP-SBJ (-NONE- *-32)) (VP (VBG increasing) (NP (NP (NN transcript) (NNS levels)) (PP (IN of) (NP (NP (DT the) (NN p50) (NN gene)) (VP (VBG coding) (PP (IN for) (NP (NP (DT the) (NN p50) (NN subunit)) (PP (IN of) (NP (DT the) (NN NF-kappa) (NN B) (NN transcription) (NN factor))))))))))))))) (, ,) (IN whereas) (S (NP-SBJ (NP (NN mRNA) (NNS levels)) (PP (IN of) (NP (DT the) (NN p65) (NN NF-kappa) (NN B) (NN gene)))) (VP (VBD remained) (ADJP-PRD (JJ unchanged)))) (. .))
